OptiNose, Inc. (OPTN)の価格はいくらですか

OptiNose, Inc. (OPTN)の価格は$9.60です

OptiNose, Inc. (OPTN)の時価総額は何ですか

OptiNose, Inc. (OPTN)の時価総額は$1.08Bです

OptiNose, Inc.（OPTN）PSR（株価売上高倍率）

OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.

年	P/S比率	変化
2026 (TTM)	1.24	42.85%
2024	0.87	-97.16%
2023	30.55	1,366.42%
2022	2.08	-88.74%
2021	18.51	-69.68%
2020	61.04	-63.50%
2019	167.24	-68.05%
2018	523.46	0.00%
2017	0.00	-100.00%
2016	16.31	-99.98%
2015	89.58K	0.00%

年

P/S比率

変化

2026 (TTM)

1.24

42.85%

2024

0.87

-97.16%

2023

30.55

1,366.42%

2022

2.08

-88.74%

2021

18.51

-69.68%

2020

61.04

-63.50%

2019

167.24

-68.05%

2018

523.46

0.00%

2017

0.00

-100.00%

2016

16.31

-99.98%

2015

89.58K

0.00%

企業	P/S比率	P/S比率の差	国
MERCK Kommanditgesellschaft auf Aktien MER.SW	-	-	DE
Merck KGaA MRK.DE	-	-	DE
Takeda Pharmaceutical Company Limited 4502.T	-	-	JP
Galderma Group AG GALD.SW	-	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	7.73	521.93%	IN

企業

P/S比率

P/S比率の差

国